The CLIN1 award provided by CIRM for the preclinical development of QXL138AM supported the successful GMP manufacturing of QXL138AM to provide clinical drug supply required for the first-in-human Phase 1 study. In addition, it supported studies that furthered our understanding of the safety, mechanism of action, efficacy and pharmacokinetics of QXL138AM. Lastly, the funding supported activities required to initiate the Phase 1 clinical study, including filing of the IND and subsequent receipt of FDA “allowed to proceed with clinical activities”, at multiple clinical sites throughout California as well as across the United States.